NEW YORK, Dec 31, 2025, 1:25 ET
- Lupin said its VISUfarma acquisition is now expected to close by Feb. 28, 2026, extending its earlier end-2025 timeline. 1
- Separately, Lupin signed an exclusive India licensing and supply deal with China’s Gan & Lee for bofanglutide, a fortnightly GLP-1 diabetes and weight-loss injection. 2
- The moves underscore Lupin’s push to expand in specialty ophthalmology and tap fast-growing demand for obesity and diabetes medicines. 3
Lupin said the closing timeline for its acquisition of Dutch eye-care company VISUfarma has been extended, with the transaction now expected to be completed by Feb. 28, 2026. 1
The delay matters because Lupin has pitched VISUfarma as a pillar of its specialty strategy in Europe, and the revised date pushes the deal past the company’s earlier goal of closing by the end of 2025. 3
Lupin said the VISUfarma transaction is progressing and remains subject to customary closing conditions. 4
VISUfarma, based in the Netherlands, would be acquired through Lupin’s wholly owned subsidiary Nanomi, Lupin has said. 1
Lupin announced the VISUfarma deal in late September, saying it would strengthen its global specialty ophthalmology business and broaden its portfolio in areas such as dry eye and glaucoma. 3
The company also said at the time that it planned to finance the acquisition using existing cash on its balance sheet. 3
In a separate development this week, Lupin said it struck an exclusive license, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for bofanglutide, a novel GLP-1 receptor agonist designed for once-every-two-weeks dosing. 2
GLP-1 medicines mimic a gut hormone that helps regulate blood sugar and appetite, and have become a major battleground for drugmakers targeting diabetes and obesity. 2
Under the agreement, Lupin will have exclusive rights to commercialize and distribute bofanglutide in India, it said. 2
“We are committed to offering the best solutions for managing chronic metabolic diseases like Diabetes,” Lupin Managing Director Nilesh Gupta said in a statement. 2
The Gan & Lee pact adds to Lupin’s efforts to expand beyond its core generics franchise into specialty products and higher-growth therapeutic areas. 2
